WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H121219
CAS#: 1415321-64-0
Description: SR10221 is a PPARγ inverse-agonist. SR10221 represses downstream PPARγ target genes leading to growth inhibition in bladder cancer cell lines.
Hodoodo Cat#: H121219
Name: SR10221
CAS#: 1415321-64-0
Chemical Formula: C33H37ClN2O4
Exact Mass: 560.24
Molecular Weight: 561.120
Elemental Analysis: C, 70.64; H, 6.65; Cl, 6.32; N, 4.99; O, 11.41
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: SR10221; SR-10221 SR 10221
IUPAC/Chemical Name: (S)-2-(5-((5-(((S)-1-(4-(tert-butyl)phenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)-2-chlorophenoxy)propanoic acid
InChi Key: NPMSSJHJPGMEJW-UNMCSNQZSA-N
InChi Code: InChI=1S/C33H37ClN2O4/c1-19-21(3)36(18-23-8-14-28(34)30(16-23)40-22(4)32(38)39)29-15-11-25(17-27(19)29)31(37)35-20(2)24-9-12-26(13-10-24)33(5,6)7/h8-17,20,22H,18H2,1-7H3,(H,35,37)(H,38,39)/t20-,22-/m0/s1
SMILES Code: CC1=C(C)N(CC2=CC(O[C@@H](C)C(O)=O)=C(Cl)C=C2)C(C1=C3)=CC=C3C(N[C@@H](C)C4=CC=C(C(C)(C)C)C=C4)=O
Appearance: To be determined
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: To be determined
Shelf Life: >2 years if stored properly
Drug Formulation: To be determined
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
Biological target: | |
In vitro activity: | |
In vivo activity: |
The following data is based on the product molecular weight 561.12 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Formulation protocol: | |
In vitro protocol: | |
In vivo protocol: |
Irwin S, Karr C, Furman C, Tsai J, Gee P, Banka D, Wibowo AS, Dementiev AA, O'Shea M, Yang J, Lowe J, Mitchell L, Ruppel S, Fekkes P, Zhu P, Korpal M, Larsen NA. Biochemical and structural basis for the pharmacological inhibition of nuclear hormone receptor PPARγ by inverse agonists. J Biol Chem. 2022 Sep 28;298(11):102539. doi: 10.1016/j.jbc.2022.102539. Epub ahead of print. PMID: 36179791; PMCID: PMC9626935.